ReviewCancers2022
Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Dense Plasma Cell Infiltrates Foster Stromal Desmoplasia and Immune Evasion in Oral Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease.PLoS neglected tropical diseases · 2026Article
- Radical Quenching and LOX Inhibiting Properties of Indole Derivatives: A Plausible Mechanism of Action Through HAT, SET-PT and SPLET Pathway.Journal of fluorescence · 2026Article
- Fibrosis of Periprostatic Adipose Tissue: A Potential Marker of Prostate Cancer Aggressiveness.Cancers · 2026Article
- Induction chemotherapy administration increases the risk of radiation pneumonitis in unresectable stage III NSCLC patients undergoing concurrent chemoradiotherapy with immunotherapy.Therapeutic advances in medical oncology · 2026Article
- Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates.Nutrition and metabolic insights · 2026Review
- Molecular insights of a Unani formulation in targeting fibrosis-associated diseases.Frontiers in pharmacology · 2026Review
- The immune microenvironment of pathogen-associated cancers and current clinical therapeutics.Molecular cancer · 2025Review
- Quercetin targets TGFβ-primed human MDA-MB-231 triple-negative breast cancer cells, linking epithelial-mesenchymal transition to cell senescence and fibrosis.Molecular biology reports · 2025Article
- The impact of serpinB3-PD polymorphism on the prognosis of patients with hepatocellular carcinoma.Translational oncology · 2025Article
- Mechanisms of Lung Cancer Development in Cystic Fibrosis Patients: The Role of Inflammation, Oxidative Stress, and Lung Microbiome Dysbiosis.Biomolecules · 2025Review
- Cardiac Metastasis: Epidemiology, Pathophysiology, and Clinical Management.Life (Basel, Switzerland) · 2025Review
- Article
- LncRNA SLC7A11AR promotes lung adenocarcinoma progression by inhibiting ferroptosis via promoting SLC7A11 expression.International journal of biological sciences · 2025Article
- Sclareol exerts an anti-inflammatory effect, possibly through COXs inhibition pathway:Pharmaceutical science advances · 2024Article
- Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.International journal of colorectal disease · 2024Review
- Review
- Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic Cancer.Cureus · 2024Article
- LMK-235 suppresses osteoclastogenesis and promotes osteoblastogenesis by inhibiting HDAC4.Scientific reports · 2024Article
- From viruses to cancer: exploring the role of the hepatitis C virus NS3 protein in carcinogenesis.Infectious agents and cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Uncontrolled inflammation is a salient factor in multiple chronic inflammatory diseases and cancers. In this review, we provided an in-depth analysis of the relationships and distinctions between uncontrolled inflammation, fibrosis and cancers, while emphasizing the challenges and opportunities of developing novel therapies for the treatment and/or management of these diseases. We described how drug delivery systems, combination therapy and the integration of tissue-targeted and/or pathways selective strategies could overcome the challenges of current agents for managing and/or treating chronic inflammatory diseases and cancers. We also recognized the value of the re-evaluation of the disease-specific roles of multiple pathways implicated in the pathophysiology of chronic inflammatory diseases and cancers-as well as the application of data from single-cell RNA sequencing in the success of future drug discovery endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.